Want to see RNXT full AI Analyst Report?
RenovoRx (RNXT) Stock Statistics & Valuation Metrics
Total Valuation
RenovoRx has a market cap or net worth of $54.52M. The enterprise value is $65.14M.
- Market Cap
- $54.52M
- Enterprise Value
- $65.14M
Share Statistics
RenovoRx has 48,250,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 48,250,590
- Owned by Insiders
- 3.29%
- Owned by Institutions
- 16.32%
Financial Efficiency
RenovoRx’s return on equity (ROE) is -2.06 and return on invested capital (ROIC) is -200.55%.
- Return on Equity (ROE)
- -2.06
- Return on Assets (ROA)
- -1.38
- Return on Invested Capital (ROIC)
- -200.55%
- Return on Capital Employed (ROCE)
- -2.04
- Revenue Per Employee
- 66.06K
- Profits Per Employee
- -656.94K
- Employee Count
- 17
- Asset Turnover
- 0.14
- Inventory Turnover
- 1.73
Valuation Ratios
The current PE Ratio of RenovoRx is -3.57. RenovoRx’s PEG ratio is -0.28.
- PE Ratio
- -3.57
- PS Ratio
- 18.37
- PB Ratio
- 5.87
- Price to FCF
- -4.17
- Price to Operating Cash Flow
- -4.49
- PEG Ratio
- -0.28
Income Statement
In the last 12 months, RenovoRx had revenue of 1.12M and earned -11.17M in profits. Earnings per share was -0.32.
- Revenue
- 1.12M
- Gross Profit
- 796.00K
- Operating Income
- -12.51M
- Pretax Income
- -11.17M
- Net Income
- -11.17M
- EBITDA
- -11.17M
- Earnings Per Share (EPS)
- -0.32
Cash Flow
In the last 12 months, operating cash flow was -12.13M and capital expenditures -90,000, giving a free cash flow of -12.22M billion.
- Operating Cash Flow
- -12.13M
- Free Cash Flow
- -12.22M
- Free Cash Flow per Share
- -0.25
Dividends & Yields
RenovoRx pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.97%
- Earnings Yield
- -23.91%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- 17.10%
- 50-Day Moving Average
- 1.56
- 200-Day Moving Average
- 1.11
- Relative Strength Index (RSI)
- 37.31
- Average Volume (3m)
- 820.10K
Important Dates
RenovoRx upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 06, 2027
- Ex-Dividend Date
- ―
Financial Position
RenovoRx as a current ratio of 4.02, with Debt / Equity ratio of 3.91%
- Current Ratio
- 4.02
- Quick Ratio
- 3.93
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.61
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, RenovoRx has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
RenovoRx EV to EBITDA ratio is -3.24, with an EV/FCF ratio of -3.34.
- EV to Sales
- 14.70
- EV to EBITDA
- -3.24
- EV to Free Cash Flow
- -3.34
- EV to Operating Cash Flow
- -3.36
Balance Sheet
RenovoRx has $10.40M in cash and marketable securities with $225.00K in debt, giving a net cash position of $10.18M billion.
- Cash & Marketable Securities
- $10.40M
- Total Debt
- $225.00K
- Net Cash
- $10.18M
- Net Cash Per Share
- $0.21
- Tangible Book Value Per Share
- $0.19
Margins
Gross margin is 84.04%, with operating margin of -483.93%, and net profit margin of -469.02%.
- Gross Margin
- 84.04%
- Operating Margin
- -483.93%
- Pretax Margin
- -469.06%
- Net Profit Margin
- -469.02%
- EBITDA Margin
- -454.00%
- EBIT Margin
- -337.68%
Analyst Forecast
The average price target for RenovoRx is $7.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $7.13
- Price Target Upside
- 530.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 199.14%
- EPS Growth Forecast
- 12.75%
Scores
- Smart Score
- 8
- AI Score
- 48
